Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Efficacy of the irreversible pan-HER tyrosine kinase inhibitor, neratinib, consistent with the results in the overall NALA population
Findings at 4-year follow-up in East Asian patients with advanced HR-positive, HER2-negative breast cancer are consistent with those in the overall MONARCH 2 study population
The most widely used therapies and subsequent outcomes were identified with the aim of informing T-cell lymphoma treatment
Data from the subgroup of patients from Asia-Pacific with pretreated triple negative breast cancer were similar to that observed in overall KEYNOTE-119 study population
The Japan subset showed similar progression-free survival to the overall PAOLA-1 population
Chinese patients receiving niraparib, a potent inhibitor of PARP 1/2, benefited from an individualised starting dose
Findings from a first phase II study of this combination in nasopharyngeal carcinoma
Patients enrolled from Asia demonstrated consistent findings with those in the overall population of the KEYNOTE-355 study
Subgroup of Asian patients with triple negative breast cancer demonstrates similar reponse as observed in patients overall in the KEYNOTE-522 study
The benefits in patients with advanced ovarian cancer and a BRCA mutation lasted well-beyond the two-year olaparib maintenance treatment
Findings of the Chinese phase II study with novel, orally administered tyrosine kinase inhibitor
Envafolimab provided responses across various tumour types
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
